VOR
Vor Biopharma Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$19.68Close
$762.0MMarket cap
$6.86 – $25.1052-week range
Nov 12, 2026Next report
Highlights
Cautions
- Trend not confirmed 6 of 8 conditions · under the 50-day, RS under 70
- Results soon Nov 12, 2026, in 11 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
22%
1wk
up 7.8%
price change
1mo
up 3.1%
price change
12-month return
down 21%
market up 11% ·
its own down 34%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
down 101.7%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
—
return on equity
Free cash margin
—
-$143.7M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
6.3%
$1.24 a day · 2×ATR $17.21
RS
64 / 99
vs the universe
Trend
6 / 8
under the 50-day, RS under 70
Relative volume
0.8×
vs 50-day average
Up/down volume
0.84
50 sessions
Implied move
—
no option chain · report Nov 12, 2026
Trend template · 6 of 8
- Price above the 50-day average: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$164.3M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Shareholders diluted The share count rose 520.6% over the year, from 6m to 39m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Jan 12, 2026
Last shock
Sep 23, 2026-12% in one session2.9× volumeno filing matched+2% since
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$43.4M | -$69.0M | -$93.4M | -$126.0M | -$121.2M | -$371.6M |
| Net income | -$43.3M | -$68.9M | -$92.1M | -$117.9M | -$116.9M | -$696.0M |
| Earnings per share | — | -$41.22 | -$46.57 | -$35.08 | -$34.03 | -$70.50 |
| Free cash flow | -$40.5M | -$73.0M | -$93.6M | -$101.4M | -$99.9M | -$143.7M |
| Cash | $48.5M | $119.8M | $57.7M | $31.4M | $81.9M | $396.5M |
| Shareholders' equity | -$59.1M | $216.3M | $250.6M | $150.7M | $96.7M | -$164.3M |
| Shares outstanding | 25.25k | 1.86m | 3.30m | 3.39m | 6.24m | 38.72m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 30, 2026 | Quarterly ↗ | Sep 30, 2026 | 30d |
| Aug 11, 2026 | Quarterly ↗ | Jun 30, 2026 | 42d |
| May 13, 2026 | Quarterly ↗ | Mar 31, 2026 | 43d |
| Mar 30, 2026 | Annual ↗ | Dec 31, 2025 | 89d |
| Nov 13, 2025 | Quarterly ↗ | Sep 30, 2025 | 44d |
| Aug 12, 2025 | Quarterly ↗ | Jun 30, 2025 | 43d |
| May 14, 2025 | Quarterly ↗ | Mar 31, 2025 | 44d |
| Mar 20, 2025 | Annual ↗ | Dec 31, 2024 | 79d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Mar 20, 2024 | Annual ↗ | Dec 31, 2023 | 80d |
Current reports
| Filed | Disclosed |
|---|---|
| Jul 7, 2026 | Director or officer change ↗ |
| Jun 12, 2026 | Shareholder vote ↗ |
| Jun 8, 2026 | Regulation FD ↗ |
| Mar 27, 2026 | Material agreement · Unregistered share sale · Regulation FD ↗ |
| Jan 12, 2026 | Results · Regulation FD ↗ |
| Jan 2, 2026 | Director or officer change ↗ |
| Dec 18, 2025 | Material agreement · Unregistered share sale · Director or officer change · Regulation FD ↗ |
| Dec 9, 2025 | Director or officer change ↗ |
| Nov 12, 2025 | Other events ↗ |
| Nov 3, 2025 | Director or officer change · Regulation FD ↗ |
| Oct 28, 2025 | Regulation FD ↗ |
| Sep 17, 2025 | Holder rights changed · Other events ↗ |